TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35077606
Drug: MZ-004 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: MZ-004 900 μg
Study: 35077606
Drug: MZ-004 1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MZ-004 1200 μg
Study: 35077606
Drug: MZ-004 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: MZ-004 (both doses)
Study: 33278280
Drug: Early pregnancy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early pregnancy loss treatment
Study: 32482490
Drug: CVT-301 (levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVT-301 (levodopa inhalation powder) 84 mg (+25 mg of oral carbidopa)
Study: 32482490
Drug: Oral carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbidopa/levodopa (25/100 mg)
Study: 33836658
Drug: Lidocaine coinfusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine coinfusion (1 mg/kg bolus followed by 2 mg/kg/h infusion)
Study: 33836658
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (equivalent volume bolus and infusion)
Study: 33393600
Drug: Twin mix
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twin mix (2% lidocaine with 1:200,000 epinephrine and 1 mL of 4 mg dexamethasone)
Study: 36057658
Drug: Combined complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined complex decongestive therapy (CDT) with therapeutic ultrasound
Study: 36057658
Drug: Combined complex
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined complex decongestive therapy (CDT) with faradic current
Study: 36057658
Drug: Complex decongestive
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex decongestive therapy (CDT) alone (Control)
Study: 34289784
Drug: Calcipotriol 0.005%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 0.005% cream
Study: 34289784
Drug: Topical corticosteroid;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroid; Clobetasone butyrate 0.05% cream
Study: 36176149
Drug: Robot-Assisted Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-Assisted Therapy protocol with gesture training
Study: 34366306
Drug: TRADE: worksite
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRADE: worksite PA education with a manual plus American College of Sports Medicine guided PA prescription
Study: 34570799
Drug: Self-collected rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-collected rectal specimens
Study: 32652243
Drug: 5 tablets
Normalized name: Xpovio 100 MG Weekly Dose Carton Pack, 4 Blister Cards, 5 Tablets Each
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 tablets of 5‐mg oxycodone
Study: 32652243
Drug: 10 tablets
Normalized name: ALLANTOIN 0.11 in 600 mg VAGINAL TABLET [Jilgyungyi (10 Tablets)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 tablets of 5‐mg oxycodone
Study: 32613345
Drug: Laparoscopic partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic partial mesorectal excision (L‐PME)
Study: 35275166
Drug: Multicomponent safety
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent safety intervention including education on fall prevention, home medication review, home safety assessment, and occupational therapy home visits.
Study: 33891508
Drug: Oral treatment
Normalized name: Other agents for local oral treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral treatment for 8 weeks
Study: 35536547
Drug: Autologous dendritic
Normalized name: COVID19 s-vax loaded autologous dendritic cell vaccine
DrugBank: COVID19 s-vax loaded autologous dendritic cell vaccine (DB15814)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dendritic cell vaccine (DCVAC)
Study: 33483965
Drug: Intermittent serial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent serial casting in conjunction with occupational therapy and botulinum neurotoxin A (BoNT‐A)
Study: 33483965
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving BoNT‐A and occupational therapy without casting
Study: 34561890
Drug: High-sensitivity cardiac
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity cardiac troponin T (hs-cTnT) > 14 ng/l
Study: 34561890
Drug: High-sensitivity cardiac
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sensitivity cardiac troponin T (hs-cTnT) ≤ 14 ng/l
Study: 37125529
Drug: ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ramipril 5 mg
Study: 34166970
Drug: Intensive PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive PCA treatment (3 hours/day, 4 days/week for 2.5 weeks)
Study: 34166970
Drug: Standard PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard PCA treatment (1 hour/day, 3 days/week for 10 weeks)
Study: 36001989
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg daily alone
Study: 33785069
Drug: Remifentanil (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (3 to 4 μg/kg)
Study: 33785069
Drug: Rapid-onset paralytic
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid-onset paralytic agents (succinylcholine or rocuronium 1 mg/kg)
Study: 32390164
Drug: Thiamidol applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamidol applied four times daily
Study: 32390164
Drug: Thiamidol applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiamidol applied two times daily
Study: 32956479
Drug: Cyclopentolate 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclopentolate 1% as spray
Study: 32737814
Drug: Gambling Symptom
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gambling Symptom Assessment Scale (G-SAS) scores
Study: 35915198
Drug: Abemaciclib 200
Normalized name: abemaciclib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 200 mg monotherapy twice daily with a meal
Study: 35915198
Drug: Abemaciclib 200
Normalized name: abemaciclib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 200 mg monotherapy twice daily in a modified fasting state
Study: 35915198
Drug: Abemaciclib 200
Normalized name: abemaciclib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abemaciclib 200 mg monotherapy twice daily without regard to food
Study: 34880615
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray plus newly initiated antidepressant
Study: 37792613
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray
Study: 33325785
Drug: Adjuvanted Escherichia
Normalized name: escherichia coli
DrugBank: Escherichia coli (DB16539)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted Escherichia coli adhesin vaccine
Study: 33507550
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g glucose drink
Study: 34664858
Drug: Neurofeedback combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurofeedback combined with acupuncture treatment
Study: 34514678
Drug: PEG‐IFN‐? monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN‐? monotherapy
Study: 34514678
Drug: PEG‐IFN‐? plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG‐IFN‐? plus NA de novo combination
Study: 34514678
Drug: NA monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA monotherapy
Study: 32432553
Drug: Tablet intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet intervention consisting of information about IPV and safety behaviors during prenatal care.
Study: 32432553
Drug: Tablet intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet intervention (video to promote safety behaviors delivered on a tablet).
Study: 32432553
Drug: Tablet intervention.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet intervention.
Study: 35031147
Drug: Intradermal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal administration using Immucise™
Study: 35031147
Drug: Standard subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard subcutaneous (SC) administration of seasonal influenza vaccine
Study: 34690144
Drug: Memantine 10
Normalized name: Memantine 10mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 10 mg bid (24-week unblinded active-dose therapeutic trial)
Study: 35560363
Drug: mnemoPQQ® (21.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: mnemoPQQ® (21.5 mg/day)
Study: 33231105
Drug: Combination doses
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination doses of ketamine and dexmedetomidine, given intranasally
Study: 33231105
Drug: Optimal combination
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal combination therapy
Study: 32563171
Drug: Perampanel (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel (up to 8 mg/day during double-blind phase, up to 12 mg/day during open-label extension phase)
Study: 35045098
Drug: 12% carbohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12% carbohydrate beverage (250 ml bolus containing 30 g maltodextrin and 30 g sucrose)
Study: 32907375
Drug: Aquatic high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic high intensity interval training (10 weeks, twice weekly, consisting of 10 one-minute exercise intervals with one-minute rest, achieving ⩾80% of peak heart rate)
Study: 36126505
Drug: Adhesive application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhesive application after HF surface treatment
Study: 36126505
Drug: Adhesive application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adhesive application after MEP surface treatment
Study: 33587824
Drug: Fitusiran 50
Normalized name: Fitusiran
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitusiran 50 mg
Study: 33587824
Drug: Fitusiran 80
Normalized name: Fitusiran
DrugBank: Fitusiran (DB15002)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitusiran 80 mg
Study: 34607519
Drug: Pertuzumab injection
Normalized name: pertuzumab Injection
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pertuzumab injection (5 mg/kg)
Study: 34607519
Drug: Perjeta® (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perjeta® (5 mg/kg)
Study: 32463456
Drug: Osimertinib, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib, 80 mg daily and Bevacizumab, 15 mg/kg once every 3 weeks
Study: 36443896
Drug: Group-format multi-component
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-format multi-component programme based on cognitive behavioural therapy and positive psychology (6 sessions, 10 weeks)
Study: 32583557
Drug: Investigator's choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator's choice of therapy (IC)
Study: 33686559
Drug: ECMO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: ECMO treatment
Study: 34128810
Drug: Passive controls
Normalized name: RESPIRATORY TUBE 22MM PASSIVE R#1147378
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive controls (no treatment or waitlist)
Study: 32829060
Drug: Intravenous glycerol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous glycerol and dexamethasone
Study: 35916920
Drug: Combination arm
Normalized name: ARM-210
DrugBank: ARM-210 (DB16944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination arm (RE + sorafenib)
Study: 36135935
Drug: MH‐SR (500 mg/tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MH‐SR (500 mg/tablet)
Study: 36135935
Drug: Glucophage®‐XR (500 mg/tablet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucophage®‐XR (500 mg/tablet)
Study: 34805718
Drug: RT plus
Normalized name: Recort Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT plus investigational agent (A)
Study: 32768001
Drug: ECCO2R therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ECCO2R therapy for ARDS
Study: 32768001
Drug: ECCO2R therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ECCO2R therapy for ae‐COPD
Study: 34967166
Drug: Longidaza 3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longidaza 3000 ME therapy in combination with tamsulosin
Study: 34967166
Drug: Longidaza 3000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longidaza 3000 ME therapy
Study: 35092722
Drug: Everolimus (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (7.5 mg daily for first 3 days, 5.0 mg daily for days 4 and 5)
Study: 33368026
Drug: Combination viloxazine
Normalized name: viloxazine
DrugBank: Viloxazine (DB09185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination viloxazine ER (700 mg) + methylphenidate (36 mg)
Study: 33368026
Drug: Viloxazine ER
Normalized name: viloxazine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viloxazine ER (700 mg) alone
Study: 33368026
Drug: Methylphenidate (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (36 mg) alone
Study: 32027763
Drug: Adapted evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapted evidence-based intervention from U.S. for disruptive behavior disorders (DBDs) in Uganda, details on dosage and duration not available.
Study: 32665034
Drug: Dexmedetomidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine infusion (0.6 μg/kg for 10 min after central vein catheterization, followed by 0.4 μg/kg/h until the end of surgery)
Study: 35906554
Drug: Opioid-free anesthesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-free anesthesia with dexmedetomidine (loading dose 0.6 μg·kg−1 for 10 min, then 0.5 μg·kg−1·h−1 continuous infusion) and sevoflurane plus bilateral paravertebral blockade (0.2 μg·kg−1 dexmedetomidine and 0.5% ropivacaine 15 ml per side)
Study: 35906554
Drug: Opioid-based anesthesia
Normalized name: Opioid anesthetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-based anesthesia with remifentanil, sevoflurane, and bilateral paravertebral blockade (0.5% ropivacaine 15 ml per side)
Study: 34910136
Drug: Anacetrapib 100
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib 100 mg daily
Study: 32645771
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric Oxide (NO) administration during cardiopulmonary bypass (CPB)
Study: 32645771
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration during cardiopulmonary bypass (CPB)
Study: 34083615
Drug: Anfibatide administered
Normalized name: Anfibatide
DrugBank: Anfibatide (DB15094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anfibatide administered intravenously as a single dose bolus or a bolus followed by a constant rate infusion for 24 hours
Study: 34920734
Drug: Aspirin 75
Normalized name: aspirin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 75 mg once-daily
Study: 34920734
Drug: Aspirin 300
Normalized name: aspirin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 300 mg once-daily
Study: 36131360
Drug: Febuxostat 80
Normalized name: febuxostat 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat 80 mg alone
Study: 36131360
Drug: SHR4640 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640 10 mg alone
Study: 33992100
Drug: Local exercise
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local exercise therapy
Study: 32321172
Drug: L‐asparaginase (L‐ASP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐asparaginase (L‐ASP) therapy
Study: 32321172
Drug: L‐ASP reintroduction
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐ASP reintroduction
Study: 35287591
Drug: sintilimab immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sintilimab immunotherapy combined with XELOX chemotherapy
Study: 33559248
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of Donor Health Questionnaire (DHQ) and antibody testing
Study: 32922193
Drug: Ephedrine 20
Normalized name: DM 10/PSEUDOEPHEDRINE 20MG/5ML LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine 20 mg intramuscularly
Study: 36026840
Drug: Nifedipine gastrointestinal
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine gastrointestinal therapeutic system (GITS) 30 mg once daily
Study: 33514760
Drug: RRR‐α‐tocopherol (ALC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RRR‐α‐tocopherol (ALC) at doses of 50, 75, 100, and 150 mg/kg of diet
Study: 33514760
Drug: No added
Normalized name: Soy-based no added carbohydrate infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: No added α‐tocopherol in the feed (0 dose)
Study: 34954095
Drug: Hydroxychloroquine (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (daily HCQ)
Study: 34954095
Drug: Hydroxychloroquine (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine (weekly HCQ)
Study: 32493624
Drug: Polymer bur
Normalized name: dicresulene polymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymer bur with 75% ethanol pre-treatment
Study: 36219925
Drug: Respiratory muscle
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory muscle training (RMT) with a threshold resistance device, daily, twice a day for three sets of 15 repetitions for 8 weeks
Study: 616062859
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of MKS and p21
Study: 32075406
Drug: Eptinezumab 30
Normalized name: Eptinezumab
DrugBank: Eptinezumab (DB14040)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eptinezumab 30 mg
Study: 33528063
Drug: First-line treatments
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line treatments (various types including chemotherapy and radiotherapy)
Study: 33528063
Drug: Chemotherapy (CH)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CH) and radiotherapy (RT)
Study: 33528063
Drug: Chemotherapy (CH)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CH) only
Study: 35226083
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel plus bevacizumab
Study: 35226083
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel plus placebo
Study: 35226083
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel (group C)
Study: 35610625
Drug: Elian Granules
Normalized name: Lian Fang
DrugBank: Nelumbo nucifera flower (DB14333)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elian Granules (24.2 g, two small bags, twice a day for 24 weeks)
Study: 35610625
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two small bags, twice a day for 24 weeks)
Study: 32557000
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (fractional 2940-nm Er:YAG laser + 5% amorolfine lacquer)
Study: 32557000
Drug: Monotherapy (5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (5% amorolfine lacquer)
Study: 39002945
Drug: Rivaroxaban with
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban with aspirin
Study: 35266202
Drug: Pneumatic jet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumatic jet injection (PJI) with 5-fluorouracil (5-FU) and triamcinolone acetonide (TAC)
Study: 33499847
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg ART (ig) treatment diabetic
Study: 33499847
Drug: 100 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg/kg ART (ig) treatment diabetic
Study: 33499847
Drug: 6 U/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 U/kg insulin (iH) treatment diabetic
Study: 33761461
Drug: Moderate-load (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-load (ML) half-squat priming (65% 1RM)
Study: 32567238
Drug: YiqiFumai lyophilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: YiqiFumai lyophilized injection (5.2 g/day)
Study: 33219590
Drug: Dry topical
Normalized name: Savlon Dry Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry topical heat for 7 min using two hot seed bags (N=21)
Study: 33219590
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of heat and pressure (N=20)
Study: 32221332
Drug: Sodium picosulfate/magnesium
Normalized name: CITRIC ACID/SODIUM PICOSULFATE/MAGNESIUM OXIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium picosulfate/magnesium citrate (PSMC) preparation-Bowklean
Study: 35768736
Drug: Intravenous clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous clindamycin
Study: 34405393
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (ATRA) plus oral arsenic (realgar-indigo naturalis formula)
Study: 34405393
Drug: PML-RARA transcript
Normalized name: nogapendekin alfa inbakicept-pmln Injection [Anktiva]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PML-RARA transcript level of ≥6.5% at the end of induction therapy
Study: 33020898
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone 100 mg
Study: 33020898
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone 400 mg
Study: 33020898
Drug: Matching transdermal/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching transdermal/oral placebo